207 related articles for article (PubMed ID: 36757881)
1. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract][Full Text] [Related]
2. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
4. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
5. Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma.
Strange CD; Marom EM; Ahuja J; Shroff GS; Gladish GW; Carter BW; Truong MT
Adv Anat Pathol; 2023 Jul; 30(4):280-291. PubMed ID: 36395181
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
8. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
10. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT for Staging and Restaging Malignant Mesothelioma.
Lopci E; Castello A; Mansi L
Semin Nucl Med; 2022 Nov; 52(6):806-815. PubMed ID: 35965111
[TBL] [Abstract][Full Text] [Related]
12. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
13. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations.
Shivapurkar N; Wiethege T; Wistuba II; Salomon E; Milchgrub S; Muller KM; Churg A; Pass H; Gazdar AF
J Cell Biochem; 1999 Dec; 76(2):181-8. PubMed ID: 10618635
[TBL] [Abstract][Full Text] [Related]
14. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
[TBL] [Abstract][Full Text] [Related]
15. The separation of benign and malignant mesothelial proliferations.
Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
[TBL] [Abstract][Full Text] [Related]
16. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
[TBL] [Abstract][Full Text] [Related]
20. L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well-differentiated papillary mesothelial tumours and malignant mesotheliomas.
Karpathiou G; Casteillo F; Dridi M; Papoudou-Bai A; Dumollard JM; Peoc'h M
Histopathology; 2021 Aug; 79(2):272-274. PubMed ID: 33847416
[No Abstract] [Full Text] [Related]
[Next] [New Search]
